Announcements
- Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
- Context Therapeutics Announces $100 Million Private Placement
- Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
- Context Therapeutics Reports Full Year 2023 Operating and Financial Results
- Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
- Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76
- Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results
- Context Therapeutics to Participate in Two August 2023 Investor Conferences
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.67 |
---|---|
High | 1.67 |
Low | 1.67 |
Bid | 1.61 |
Offer | 1.69 |
Previous close | 1.51 |
Average volume | 485.71 |
---|---|
Shares outstanding | 15.97m |
Free float | 14.87m |
P/E (TTM) | -- |
Market cap | 29.54m USD |
EPS (TTM) | -1.50 USD |
Data delayed at least 15 minutes, as of May 06 2024 07:11 BST.
More ▼